首页> Frontiers in endocrinology> The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D3 Analog, Inecalcitol, Has Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer.

The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D3 Analog, Inecalcitol, Has Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Justine,Vanhevel

第一单位： Laboratory of Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism (CHROMETA), Katholieke Universiteit (KU) Leuven, Leuven, Belgium.

作者： Justine,Vanhevel ^[1] ; Lieve,Verlinden ^[1] ; Shauni,Loopmans ^[1] ; Stefanie,Doms ^[1] ; Iris,Janssens ^[1] ; Sien,Bevers ^[1] ; Steve,Stegen ^[1] ; Hans,Wildiers ^[2] ; Annemieke,Verstuyf ^[1]

作者单位： Laboratory of Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism (CHROMETA), Katholieke Universiteit (KU) Leuven, Leuven, Belgium. ^[1] Department of General Medical Oncology and Multidisciplinary Breast Center Leuven, University Hospitals (UV) Leuven, Leuven, Belgium. ^[2]

关键词 breast cancer cell proliferation and survival mitochondria palbociclib vitamin D3 analog